Categories
Credit Cards

Merrill Lynch Stick to The Buy Rating of theirs for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, which is roughly 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.

The current opinion among eleven TipRanks analysts is for a modest Buy rating of shares in CVS Health, with an average price aim of $84.

The analysts price targets range from a high of $101 to a low of sixty one dolars.

In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with 4 stars on a 0 5 stars ranking scale, with an average return of 11.5 % as well as a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management strategies. The Long or retail Term Care segment includes selling of prescription medications and assortment of general merchandise.

The Health Care Benefits segment offers traditional, consumer-directed and voluntary health insurance products as well as related services, including medical, pharmacy, dental, behavioural health, healthcare relief capabilities. The Corporate segment involves in providing management as well as administrative services. The company was created by Stanley P. Goldstein as well as Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *